​

Krystal Biotech (KRYS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KRYS Stock Forecast

Krystal Biotech (KRYS) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $191.00, with a high of $220.00 and a low of $133.00. This represents a 15.97% increase from the last price of $164.70.

$120 $140 $160 $180 $200 $220 High: $220 Avg: $191 Low: $133 Last Closed Price: $164.7

KRYS Stock Rating

Krystal Biotech stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (93.33%), 1 Hold (6.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 1 14 0 Strong Sell Sell Hold Buy Strong Buy

KRYS Price Target Upside V Benchmarks

TypeNameUpside
StockKrystal Biotech15.97%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$210.33
Last Closing Price$164.70$164.70$164.70
Upside/Downside--27.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25281--11
Mar, 25271--10
Feb, 25271--10
Jan, 25281--11
Dec, 24281--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 11, 2024Dae Gon HaStifel Nicolaus$220.00$185.0018.92%33.58%
Sep 02, 2024Alec StranahanBank of America Securities$205.00$195.125.06%24.47%
Aug 12, 2024Gavin Clark-GartnerEvercore ISI$206.00$182.1713.08%25.08%
Apr 15, 2024Dae Gon HaStifel Nicolaus$204.00$169.7520.18%23.86%
Nov 07, 2022Geulah LivshitsChardan Capital$133.00$78.0570.40%-19.25%
Aug 08, 2022Geulah LivshitsChardan Capital$130.00$82.4057.77%-21.07%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 18, 2024H.C. WainwrightBuyBuyhold
Nov 04, 2024CitigroupNeutralNeutralhold
Sep 11, 2024WedbushUnderperformUnderperformhold
Aug 28, 2024H.C. WainwrightBuyBuyhold
Aug 12, 2024Evercore ISIOutperformOutperformhold
Aug 05, 2024CitigroupBuyNeutraldowngrade
Feb 27, 2024CitigroupBuyBuyhold
May 22, 2023BarclaysBuyBuyhold
Feb 28, 2023Goldman SachsBuyupgrade

Financial Forecast

EPS Forecast

$-5 $1 $7 $13 $19 $25 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.40$3.12----
Avg Forecast$-0.12$2.87$6.02$8.86$12.58$18.94
High Forecast$0.02$3.70$7.86$14.60$21.71$21.09
Low Forecast$-0.30$2.00$3.35$4.61$8.67$16.09
Surprise %-433.33%8.71%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.70M$290.51M----
Avg Forecast$36.32M$291.49M$486.01M$709.09M$919.70M$1.26B
High Forecast$52.23M$295.81M$508.48M$729.99M$941.47M$1.37B
Low Forecast$24.67M$288.73M$451.36M$688.20M$897.93M$1.11B
Surprise %39.57%-0.33%----

Net Income Forecast

$-50M $90M $230M $370M $510M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.93M$89.16M----
Avg Forecast$-3.81M$79.02M$187.05M$320.43M$416.67M$525.62M
High Forecast$613.46K$102.56M$218.25M$405.05M$602.51M$585.29M
Low Forecast$-8.24M$55.47M$93.05M$128.06M$240.71M$446.55M
Surprise %-386.76%12.84%----

KRYS Forecast FAQ

Is Krystal Biotech stock a buy?

Krystal Biotech stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Krystal Biotech is a favorable investment for most analysts.

What is Krystal Biotech's price target?

Krystal Biotech's price target, set by 15 Wall Street analysts, averages $191 over the next 12 months. The price target range spans from $133 at the low end to $220 at the high end, suggesting a potential 15.97% change from the previous closing price of $164.7.

How does Krystal Biotech stock forecast compare to its benchmarks?

Krystal Biotech's stock forecast shows a 15.97% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Krystal Biotech over the past three months?

  • April 2025: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Krystal Biotech’s EPS forecast?

Krystal Biotech's average annual EPS forecast for its fiscal year ending in December 2025 is $6.02, marking a 92.95% increase from the reported $3.12 in 2024. Estimates for the following years are $8.86 in 2026, $12.58 in 2027, and $18.94 in 2028.

What is Krystal Biotech’s revenue forecast?

Krystal Biotech's average annual revenue forecast for its fiscal year ending in December 2025 is $486.01M, reflecting a 67.29% increase from the reported $290.52M in 2024. The forecast for 2026 is $709.09M, followed by $919.7M for 2027, and $1.26B for 2028.

What is Krystal Biotech’s net income forecast?

Krystal Biotech's net income forecast for the fiscal year ending in December 2025 stands at $187.05M, representing an 109.79% increase from the reported $89.16M in 2024. Projections indicate $320.43M in 2026, $416.67M in 2027, and $525.62M in 2028.